Skip to Main Content

Paper Details

Targeting autocrine amphiregulin robustly and reproducibly inhibits ovarian cancer in a syngeneic model: roles for wildtype p53.
Oncogene
7
2021
AREG, AREG's promoter, CXCL1, EGFR, OvCA, OvCa, Ovarian cancer, TP53, advanced OvCa, amphiregulin, epidermal growth factor receptor, malignancies, mice, murine, murine AREG, ovarian cancer, p53, patients, wildtype TP53, wildtype p53
Author NameAffiliation
Keren LevanonSheba Cancer Research Centre, Chaim Sheba Medical Center and Sackler Faculty of Medicine, Tel Aviv University
Iain A McNeishImperial College and Hammersmith Hospital
  • 1 - 2

Datasets

Release 1.2